Guy J Leclerc
Overview
Explore the profile of Guy J Leclerc including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
316
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sun G, Leclerc G, Chahar S, Barredo J
Mol Cancer Res
. 2023 Sep;
21(12):1261-1273.
PMID: 37682252
Implications: Fully delineating the protein interactome by which AMPK regulates adaptive survival responses to energy/metabolic stress, either via epigenetic gene regulation or other mechanisms, will allow the rational development of...
2.
Sun G, Shvab A, Leclerc G, Li B, Beckedorff F, Shiekhattar R, et al.
Mol Cancer Res
. 2021 May;
19(8):1296-1307.
PMID: 33980612
Acute lymphoblastic leukemia (ALL) is a leading cause of cancer-related death in children and adolescents, and cure rates for relapsed/refractory ALL remain dismal, highlighting the need for novel targeted therapies....
3.
Leclerc G, Zheng S, Leclerc G, DeSalvo J, Swords R, Barredo J
Leuk Res
. 2016 Sep;
50:1-10.
PMID: 27626202
Acute lymphoblastic leukemia (ALL) is the leading cause of cancer-related death in children, and cure rates for adults remain dismal. Further, effective treatment strategies for relapsed/refractory ALL remain elusive. We...
4.
Leclerc G, DeSalvo J, Du J, Gao N, Leclerc G, Lehrman M, et al.
Leuk Res
. 2015 Sep;
PMID: 26346348
BCR-ABL positive (+) acute lymphoblastic leukemia (ALL) accounts for ∼30% of cases of ALL. We recently demonstrated that 2-deoxy-d-glucose (2-DG), a dual energy (glycolysis inhibition) and ER-stress (N-linked-glycosylation inhibition) inducer,...
5.
Leclerc G, Leclerc G, Kuznetsov J, DeSalvo J, Barredo J
PLoS One
. 2013 Sep;
8(8):e74420.
PMID: 24009772
The outcome of patients with resistant phenotypes of acute lymphoblastic leukemia (ALL) or those who relapse remains poor. We investigated the mechanism of cell death induced by metformin in Bp-...
6.
DeSalvo J, Kuznetsov J, Du J, Leclerc G, Leclerc G, Lampidis T, et al.
Mol Cancer Res
. 2012 Jun;
10(7):969-78.
PMID: 22692960
The ability to pair the regulation of metabolism and cellular energetics with oncogenes and tumor suppressor genes provides cancer cells with a growth and survival advantage over normal cells. We...
7.
Kuznetsov J, Leclerc G, Leclerc G, Barredo J
Mol Cancer Ther
. 2011 Jan;
10(3):437-47.
PMID: 21262957
AICAr is a cell-permeable nucleotide that has been used in vivo and in vitro to activate AMPK. Our previous findings have shown that AICAr as a single agent induces dose-...
8.
Leclerc G, Leclerc G, Fu G, Barredo J
J Mol Signal
. 2010 Sep;
5:15.
PMID: 20863384
Background: Children with Acute Lymphoblastic Leukemia (ALL) diagnosed with resistant phenotypes and those who relapse have a dismal prognosis for cure. In search for novel treatment strategies, we identified the...
9.
Leclerc G, Sanderson C, Hunger S, Devidas M, Barredo J
Leuk Res
. 2010 Jun;
34(12):1601-9.
PMID: 20538338
Acute Lymphoblastic Leukemia (ALL) non-random fusions influence clinical outcome and alter the accumulation of MTX-PGs in vivo. Analysis of primary ALL samples uncovered subtype-specific patterns of folate gene expression. Using...
10.
Sengupta T, Leclerc G, Hsieh-Kinser T, Leclerc G, Singh I, Barredo J
Mol Cancer
. 2007 Jul;
6:46.
PMID: 17623090
Background: Acute lymphoblastic leukemia (ALL) is the most common hematological malignancy affecting children. Despite significant progress and success in the treatment of ALL, a significant number of children continue to...